查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870956

Eylea市場按適應症、最終用戶、分銷管道和給藥頻率分類 - 全球預測 2025-2032

Eylea Market by Indication, End User, Distribution Channel, Dosage Frequency - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Eylea 市場規模將成長至 127.5 億美元，複合年成長率為 7.30%。

主要市場統計數據
基準年 2024 72.5億美元
預計年份：2025年 77.7億美元
預測年份：2032年 127.5億美元
複合年成長率 (%) 7.30%

全面介紹艾力達不斷演變的臨床角色、變革性的醫療服務模式以及影響相關人員決策的分銷因素。

艾力雅（Eylea）是一種廣泛使用的玻璃體內注射抗血管內皮生長因子（VEGF）療法，由於其在多種適應症中療效顯著，以及支付方和醫療服務提供方動態，已成為現代視網膜疾病治療的主要手段。臨床醫師在選擇現有藥物時，越來越重視比較給藥間隔、療程和安全性，艾力雅的臨床應用也經常在此背景下進行評估。同時，治療場所從醫院門診轉向門診手術中心，以及眼科診所在常規注射中發揮越來越重要的作用，正在重塑治療路徑。

深入分析變革性市場變化（包括技術創新、支付方監管力度加大以及治療環境轉變）對艾力雅（Eylea）市場接受度的影響。

隨著技術創新、支付方行為和診療經濟學的融合，視網膜治療領域正經歷變革性的轉變，治療方法的選擇和實施方式也隨之改變。新的影像技術和真實世界數據正在最佳化治療閾值，並促成更個人化的給藥決策，這影響診所的就診效率和病患追蹤頻率。同時，支付方也加強了對藥物使用模式和預先核准流程的審查，進而影響藥物配製行為和藥物清單的編制。

分析2025年美國關稅對視網膜治療藥物供應鏈、籌資策略及分銷穩定性的影響

關稅和貿易措施的實施會對藥品供應鏈、籌資策略和價格談判產生連鎖反應。 2025年，美國關稅調整影響了製造商和經銷商的庫存規劃、合約談判和進口策略制定，促使他們重新評估成本促進因素和緊急計畫。這些政策變化導致對採購地點的審查力度加大，並加速了關於區域製造和近岸外包以降低跨境風險的討論。

可操作的細分分析突顯了適應症、臨床環境、分銷管道和給藥頻率對 Eylea 臨床上市和營運策略的影響。

細分市場分析揭示了應用模式和營運影響的細微差別，為臨床、商業和供應鏈決策提供基礎。根據適應症，Eylea 可用於治療老齡化黃斑部病變、視網膜分支靜脈阻塞症、視網膜中央靜脈阻塞、糖尿病性黃斑部水腫和糖尿病視網膜病變，每種疾病都有不同的患者特徵、監測要求和長期管理目標，這些都會影響治療頻率和追蹤強度。例如，慢性糖尿病視網膜病變的治療通常需要與內分泌科和基層醫療密切合作，而靜脈阻塞病例可能需要更頻繁的干涉和影像學後續觀察。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • Eylea生物類似藥對市場獨佔權和定價構成挑戰。
  • 真實世界數據顯示治療間隔變異性及其對患者預後的影響
  • 引入「治療延長通訊協定」以減輕臨床環境中的注射負擔
  • 管線創新旨在透過緩釋植入植入延長 Eylea 的給藥間隔。
  • 針對 VEGF 和 PDGF 通道的新興聯合治療正在改變競爭格局。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：艾力達（Eylea）依適應症分類的市場

  • 老齡化黃斑部病變
  • 視網膜分支靜脈阻塞症
  • 中心性視網膜靜脈阻塞
  • 糖尿病黃斑部水腫
  • 糖尿病視網膜病變

第9章 Eylea 市場（按最終用戶分類）

  • 門診手術中心
  • 醫院
  • 眼科診所

第10章 艾利亞市場通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 依給藥頻率分類的艾力達市場

  • 根據需要
  • 每隔一個月
  • 每月

第12章 艾利亞市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 艾利亞集團市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國艾利亞市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Regeneron Pharmaceuticals, Inc.
    • Bayer Aktiengesellschaft
    • Roche Holding AG
    • Novartis AG
    • AbbVie Inc.
    • Bausch Health Companies Inc.
Product Code: MRR-1A1A064C04F0

The Eylea Market is projected to grow by USD 12.75 billion at a CAGR of 7.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.25 billion
Estimated Year [2025] USD 7.77 billion
Forecast Year [2032] USD 12.75 billion
CAGR (%) 7.30%

A comprehensive introduction framing Eylea's evolving clinical role, care delivery shifts, and distribution considerations shaping stakeholder decision-making

Eylea, a widely used intravitreal anti-VEGF therapy, has become central to contemporary retinal disease management due to its established efficacy across multiple indications and evolving payer and provider dynamics. Clinicians increasingly weigh comparative dosing cadence, durability, and safety profiles when choosing between available agents, and Eylea's clinical portfolio is routinely evaluated in that context. Concurrently, changes in delivery settings, from hospital-based clinics to ambulatory surgical centers, and the growing role of ophthalmic clinics in routine injections are reshaping care pathways.

Regulatory approvals and label extensions have expanded Eylea's footprint across indications such as Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, prompting shifts in treatment algorithms. Meanwhile, distribution dynamics spanning hospital pharmacy, online pharmacy, and retail pharmacy channels influence how institutions procure and dispense therapies. As stakeholders reassess supply arrangements and clinic workflows, an evidence-based understanding of dosing frequency patterns-spanning as needed, bimonthly, and monthly regimens-becomes essential for operational planning and patient adherence strategies.

In this introduction, the focus is to set the stage for deeper analysis by outlining the clinical, operational, and commercial forces that drive Eylea's adoption. By connecting clinical evidence to care delivery realities and distribution structures, readers can better appreciate the levers available to improve patient outcomes while maintaining fiscal and operational resilience.

An in-depth analysis of transformative market shifts driven by technological advances, evolving payer scrutiny, and site-of-care migration impacting Eylea utilization

The landscape for retinal therapeutics is undergoing transformative shifts as technological innovation, payer behavior, and site-of-care economics converge to reshape how therapies are selected and delivered. Newer imaging modalities and real-world evidence are refining treatment thresholds and enabling more personalized dosing decisions, which in turn affect clinic throughput and the cadence of patient follow-up. In parallel, payers are intensifying scrutiny on utilization patterns and prior authorization processes, influencing prescribing behavior and formulary positioning.

Operationally, the migration of procedures to ambulatory surgical centers and specialized ophthalmic clinics has altered cost structures and patient access dynamics. These site-of-care changes create opportunities for efficiencies but also introduce complexities in inventory management across hospital pharmacy, online pharmacy, and retail pharmacy channels. Moreover, evolving expectations around treatment durability have elevated the importance of dosing frequency choices; options ranging from as needed, bimonthly, to monthly regimens carry implications for adherence, clinic capacity, and long-term visual outcomes.

Collectively, these shifts demand that manufacturers, providers, and payers adopt a more integrated approach to strategy-one that aligns clinical evidence with distribution logistics, contractual terms, and patient support programs. Only through this integrated lens can stakeholders navigate the changing therapeutic ecosystem and identify sustainable pathways to deliver value.

A focused examination of how United States tariffs in 2025 reshaped pharmaceutical supply chains, procurement strategies, and distribution stability for retinal therapies

The introduction of tariffs and trade measures can create ripple effects across pharmaceutical supply chains, procurement strategies, and pricing negotiations. In 2025, United States tariff adjustments influenced how manufacturers and distributors planned inventory, negotiated contracts, and structured their import strategies, prompting a reassessment of cost drivers and contingency mechanisms. These policy changes contributed to elevated scrutiny of sourcing locations and accelerated discussions about regional manufacturing and nearshoring as ways to mitigate cross-border exposures.

As a result, contract negotiations between suppliers and health systems incorporated greater emphasis on supply-chain resiliency and clauses that address tariff pass-through, lead-time variability, and currency exposure. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy adapted their procurement strategies to ensure continuity of supply, which in turn affected stockpile policies and fulfillment models. Clinicians saw changes in availability rhythms that required flexible scheduling and patient communication tactics to preserve adherence and outcomes.

Importantly, these tariff-related dynamics intersected with broader shifts in site of care, dosing frequency preferences, and payer reimbursement practices. Consequently, healthcare stakeholders placed a premium on transparency in cost composition and a stronger alignment between commercial teams and supply-chain functions to safeguard patient access while maintaining operational predictability.

Actionable segmentation insights revealing how indication, site of care, distribution channel, and dosing frequency shape clinical adoption and operational strategies for Eylea

Segmentation analysis illuminates nuanced adoption patterns and operational implications that inform clinical, commercial, and supply-chain decisions. Based on indication, Eylea's use spans Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, each presenting distinct patient profiles, monitoring requirements, and long-term management goals that influence treatment cadence and follow-up intensity. For instance, chronic diabetic retinal disease pathways often require closer systemic coordination with endocrinology and primary care, whereas vein occlusion cases may demand more episodic intervention and imaging follow-up.

Based on end user, the market is examined across ambulatory surgical centers, hospitals, and ophthalmic clinics, with each setting presenting specific throughput constraints, staffing models, and reimbursement environments that affect regimen selection and scheduling. Distribution channel analysis encompasses hospital pharmacy, online pharmacy, and retail pharmacy, and highlights how procurement lead times, cold-chain logistics, and dispensing workflows shape clinic inventory practices and patient access points. Finally, dosing frequency segmentation considers as needed, bimonthly, and monthly approaches, which carry direct implications for adherence, clinic capacity, and long-term visual stability.

Taken together, these segmentation lenses reveal that strategic choices-ranging from contracting approaches to patient support services-must be tailored to the clinical indication, the primary site of administration, the chosen distribution pathway, and the dosing cadence to ensure both clinical effectiveness and operational efficiency.

Key regional intelligence synthesizing regulatory, payer, and delivery system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform tailored strategies

Regional dynamics exert powerful influence over regulatory pathways, payer structures, and clinical practice norms, requiring tailored approaches to commercialization and access. In the Americas, concentrated centers of retinal expertise and diverse payer models drive both high standards of evidence generation and complex contracting conversations, while supply-chain considerations emphasize regional distribution hubs and inventory resilience. Meanwhile, Europe, Middle East & Africa present a mosaic of regulatory frameworks and pricing mechanisms that necessitate differentiated engagement strategies with national health authorities and private payers.

In Asia-Pacific, rapid modernization of ophthalmic services, expanding private clinic networks, and growing investment in diagnostic infrastructure are accelerating adoption trajectories, yet heterogeneity in reimbursement and procurement processes requires nuanced market access planning. Across these regions, variations in predominant sites of care-ranging from hospital-centric models to ambulatory surgical centers and specialized ophthalmic clinics-alter operational priorities and influence decisions around dosing frequency and patient monitoring.

Consequently, a regionalized strategy that integrates regulatory intelligence, payer engagement, and localized patient support models is essential. By aligning clinical evidence with regional healthcare delivery realities and distribution capabilities, stakeholders can better navigate access barriers, optimize deployment of resources, and support consistent patient outcomes across diverse health systems.

Company level insights highlighting strategic differentiation through evidence generation, supply-chain resilience, and integrated service offerings in the retinal therapeutics space

Competitive dynamics in the retinal therapeutics space reflect a mixture of established biologics, biosimilars, and evolving delivery technologies, prompting companies to prioritize differentiation through outcomes data, patient support, and supply stability. Leading manufacturers have invested in head-to-head comparative studies, real-world evidence generation, and outcomes registries to substantiate clinical advantages and to inform payer conversations. Meanwhile, companies are strengthening their commercial propositions with services that reduce administrative burden for clinicians and patients, such as streamlined prior authorization support and coordinated injection visit pathways.

Supply-chain robustness has become a core differentiator, with industry players emphasizing multiple sourcing options, cold-chain integrity, and contractual flexibility to limit disruption from geopolitical or tariff-related shocks. Strategic partnerships between manufacturers and specialty distributors have surfaced as a method to optimize reach across hospital pharmacy, online pharmacy, and retail pharmacy channels while maintaining compliance with storage and handling requirements. Additionally, investment in digital tools for patient engagement and adherence monitoring is enhancing long-term outcomes and shaping competitive positioning.

Collectively, these company-level activities underscore a broader shift toward integrated solutions that combine clinical evidence, operational reliability, and services that reduce friction in the care pathway. For stakeholders, discerning these strategic priorities is essential when evaluating potential collaborators or benchmarking internal capabilities.

Actionable recommendations for industry leaders to align clinical evidence, supply resilience, and payer engagement while optimizing regional and site-of-care strategies

Industry leaders must take proactive steps to align clinical value with operational feasibility and payer expectations in order to sustain access and optimize patient outcomes. First, strengthen cross-functional alignment between commercial, medical affairs, and supply-chain teams to ensure that contracting terms, inventory strategies, and clinical messaging are coherent and responsive to tariff and procurement dynamics. This integrated approach reduces the risk of supply interruptions and clarifies responsibilities during periods of policy or logistical change.

Second, invest in robust real-world evidence programs and outcomes registries that demonstrate long-term visual benefits and inform payer discussions across indications such as Age-Related Macular Degeneration and Diabetic Macular Edema. Third, tailor patient support and adherence initiatives to dosing frequency realities-whether as needed, bimonthly, or monthly-to sustain visual gains while minimizing no-show rates and clinic bottlenecks. Fourth, expand distribution flexibility by cultivating relationships with hospital pharmacy, online pharmacy, and retail pharmacy partners to diversify fulfillment options and improve patient access points.

Finally, adopt a regionalized go-to-market posture that accounts for differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific, aligning regulatory engagement, reimbursement strategies, and local stakeholder outreach. By operationalizing these recommendations, organizations can build resilience, demonstrate value, and accelerate appropriate patient access.

A clear and reproducible research methodology combining primary interviews, literature synthesis, and scenario analysis to ensure rigorous evaluation of clinical and operational dynamics

This research integrates multiple evidence streams to produce a comprehensive assessment of clinical, operational, and commercial dynamics. Primary research included structured interviews with retina specialists, pharmacy procurement managers, and health system operations leaders to capture firsthand perspectives on dosing cadence, site-of-care trends, and distribution challenges. Secondary research encompassed review of peer-reviewed literature, regulatory documentation, and publicly available clinical trial results to validate clinical endpoints and safety profiles across indications including Age-Related Macular Degeneration and Diabetic Retinopathy.

Analytical methods combined qualitative synthesis with comparative scenario analysis to explore implications of dosing frequency choices-spanning as needed, bimonthly, and monthly regimens-and to assess distribution channel impacts across hospital pharmacy, online pharmacy, and retail pharmacy pathways. Regional context was developed through targeted interviews and regulatory reviews across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure findings reflect local practice patterns and access constraints. Throughout, rigorous quality control processes were applied to reconcile divergent inputs and to ensure that conclusions are grounded in verifiable evidence.

Transparency around methodology ensures that readers can interpret findings in light of data sources and analytical assumptions. For organizations seeking customized outputs, the methodology can be adapted to incorporate proprietary datasets, expanded primary interviews, or focused country-level appendices to support specific strategic decision needs.

A concise conclusion synthesizing clinical, operational, and regional imperatives to guide strategic decision-making for sustained patient access and therapeutic value

In conclusion, Eylea occupies a central role in contemporary retinal disease management, with clinical evidence and delivery models continuing to evolve in tandem. The interplay between dosing frequency preferences, site-of-care shifts, and distribution channel dynamics creates both challenges and opportunities for manufacturers, providers, and payers. Navigating this complex environment requires integrated strategies that bring together evidence generation, supply-chain resilience, and targeted payer engagement.

Moreover, regionally tailored approaches that acknowledge the distinct regulatory, reimbursement, and delivery realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific will be essential for sustaining access and improving patient outcomes. As tariff and policy landscapes change, organizations must prioritize transparency in procurement and contractual arrangements to mitigate risk. By implementing the recommended actions-strengthening cross-functional coordination, investing in real-world evidence, diversifying distribution relationships, and adapting to regional nuances-stakeholders can preserve continuity of care and enhance long-term therapeutic value.

Ultimately, decision-makers who synthesize clinical insights with operational readiness will be best positioned to support patients and health systems through a period of continued transformation in retinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of Eylea biosimilars challenging market exclusivity and pricing dynamics
  • 5.2. Real-world data revealing variable treatment intervals and impact on patient outcomes
  • 5.3. Adoption of treat-and-extend protocols to reduce injection burden in clinical practice
  • 5.4. Pipeline innovations exploring sustained-release implants to extend Eylea dosing intervals
  • 5.5. Competitive landscape shifts with emerging combination therapies targeting VEGF and PDGF pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Eylea Market, by Indication

  • 8.1. Age-Related Macular Degeneration
  • 8.2. Branch Retinal Vein Occlusion
  • 8.3. Central Retinal Vein Occlusion
  • 8.4. Diabetic Macular Edema
  • 8.5. Diabetic Retinopathy

9. Eylea Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Hospitals
  • 9.3. Ophthalmic Clinics

10. Eylea Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Eylea Market, by Dosage Frequency

  • 11.1. As Needed
  • 11.2. Bimonthly
  • 11.3. Monthly

12. Eylea Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Eylea Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Eylea Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Regeneron Pharmaceuticals, Inc.
    • 15.3.2. Bayer Aktiengesellschaft
    • 15.3.3. Roche Holding AG
    • 15.3.4. Novartis AG
    • 15.3.5. AbbVie Inc.
    • 15.3.6. Bausch Health Companies Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL EYLEA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL EYLEA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EYLEA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS EYLEA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. EYLEA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. EYLEA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. EYLEA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL EYLEA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL EYLEA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL EYLEA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL EYLEA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS EYLEA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS EYLEA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 159. AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. ASEAN EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASEAN EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASEAN EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. ASEAN EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. ASEAN EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. ASEAN EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 191. GCC EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GCC EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GCC EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. GCC EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. GCC EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GCC EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GCC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. GCC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. GCC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 200. GCC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPEAN UNION EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPEAN UNION EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPEAN UNION EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 211. BRICS EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. BRICS EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. BRICS EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. BRICS EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. BRICS EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. BRICS EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 221. G7 EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. G7 EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. G7 EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 224. G7 EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 225. G7 EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. G7 EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. G7 EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. G7 EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. G7 EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 230. G7 EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 231. NATO EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NATO EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NATO EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NATO EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NATO EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NATO EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NATO EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. NATO EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. NATO EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 240. NATO EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. UNITED STATES EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED STATES EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED STATES EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 251. CANADA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. CANADA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. CANADA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 259. MEXICO EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. MEXICO EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. MEXICO EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 267. BRAZIL EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. BRAZIL EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. BRAZIL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 283. GERMANY EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. GERMANY EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. GERMANY EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 291. FRANCE EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. FRANCE EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. FRANCE EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. FRANCE EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 299. RUSSIA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. RUSSIA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. RUSSIA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 307. ITALY EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. ITALY EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. ITALY EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. ITALY EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. ITALY EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 315. SPAIN EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. SPAIN EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. SPAIN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 323. CHINA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. CHINA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. CHINA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. CHINA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. CHINA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. CHINA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 331. INDIA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. INDIA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 333. INDIA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. INDIA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. INDIA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 336. INDIA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 339. JAPAN EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. JAPAN EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 341. JAPAN EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. JAPAN EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. JAPAN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. JAPAN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 348. AUSTRALIA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. AUSTRALIA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. AUSTRALIA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA EYLEA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 356. SOUTH KOREA EYLEA MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 357. SOUTH KOREA EYLEA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 358. SOUTH KOREA EYLEA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 359. SOUTH KOREA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 360. SOUTH KOREA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 362. SOUTH KOREA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 363. EYLEA MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 364. EYLEA MARKET, FPNV POSITIONING MATRIX, 2024